Published in Oncologist on October 17, 2013
Optimising Breast Conservation Treatment for Multifocal and Multicentric Breast Cancer: A Worthwhile Endeavour? World J Surg (2016) 1.04
Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer. Geburtshilfe Frauenheilkd (2015) 0.76
Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44. PLoS One (2017) 0.75
N-3 Polyunsaturated Fatty Acids of Marine Origin and Multifocality in Human Breast Cancer. PLoS One (2016) 0.75
Is breast conservative surgery a reasonable option in multifocal or multicentric tumors? World J Clin Oncol (2016) 0.75
Mediated coalescence: a possible mechanism for tumor cellular heterogeneity. Am J Cancer Res (2015) 0.75
Extreme oncoplastic breast surgery: A case report. Int J Surg Case Rep (2016) 0.75
Size and specimen-dependent strategy for x-ray micro-ct and tem correlative analysis of nervous system samples. Sci Rep (2017) 0.75
Optimising Breast Conservation Treatment for Multifocal and Multicentric Breast Cancer: A Worthwhile Endeavour?: Reply. World J Surg (2017) 0.75
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med (1997) 10.83
Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med (1997) 7.61
Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol (2008) 3.06
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol (1999) 2.22
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol (2000) 2.19
Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol (2004) 1.83
Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer (1982) 1.25
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.20
Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat (2010) 1.15
Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat (2008) 1.12
Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys (2010) 1.05
The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys (2001) 1.05
Breast-conserving therapy for macroscopically multiple cancers. Ann Surg (1990) 1.04
Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound. Clin Radiol (2005) 1.04
Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol (1988) 1.02
Results of conservative surgery and radiation therapy for multiple synchronous cancers of one breast. Int J Radiat Oncol Biol Phys (1989) 1.01
Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg (2008) 0.96
Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol (2006) 0.92
Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol (2012) 0.86
Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer (1993) 0.85
Breast conservation in women with multifocal-multicentric breast cancer: is it feasible? Ann Surg Oncol (2010) 0.83
The role of mastectomy in patients with stage I-II breast cancer presenting with gross multifocal or multicentric disease or diffuse microcalcifications. Int J Radiat Oncol Biol Phys (1993) 0.81
Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy? Int J Radiat Oncol Biol Phys (1994) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol (2009) 8.55
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A (2007) 4.97
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Identification of an organelle receptor for myosin-Va. Nat Cell Biol (2002) 4.06
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med (2008) 3.69
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
Accuracy and self correction of information received from an internet breast cancer list: content analysis. BMJ (2006) 3.46
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med (2008) 3.36
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol (2006) 3.34
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol (2008) 3.09
Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell (2006) 3.01
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst (2005) 2.93
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
FARP2 triggers signals for Sema3A-mediated axonal repulsion. Nat Neurosci (2005) 2.87
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Melamine related bilateral renal calculi in 50 children: single center experience in clinical diagnosis and treatment. J Urol (2010) 2.83
Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell (2013) 2.83
Complications, consequences, and practice patterns of endobronchial ultrasound-guided transbronchial needle aspiration: Results of the AQuIRE registry. Chest (2013) 2.82
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst (2011) 2.77
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol (2005) 2.72
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Improved rapid amplification of cDNA ends (RACE) for mapping both the 5' and 3' terminal sequences of paramyxovirus genomes. J Virol Methods (2005) 2.66
Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet (2008) 2.65
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol (2009) 2.64
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell (2006) 2.61
Isolation of spermatozoa with low levels of fragmented DNA with the use of flow cytometry and sorting. Fertil Steril (2013) 2.60
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
C. elegans screen identifies autophagy genes specific to multicellular organisms. Cell (2010) 2.50
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics (2004) 2.49
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol (2011) 2.43
Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol (2014) 2.42
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol (2008) 2.40
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol (2012) 2.40
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol (2005) 2.39
Guidance of myocardial patterning in cardiac development by Sema6D reverse signalling. Nat Cell Biol (2004) 2.39
Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol (2012) 2.38
SEPA-1 mediates the specific recognition and degradation of P granule components by autophagy in C. elegans. Cell (2009) 2.35
Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A (2005) 2.31
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis (2008) 2.31
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol (2011) 2.29
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer (2003) 2.29
Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys (2009) 2.27
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res (2009) 2.24
Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. J Occup Environ Med (2006) 2.24
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol (2006) 2.23
Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. Genes Dev (2004) 2.22
Histone demethylase UTX-1 regulates C. elegans life span by targeting the insulin/IGF-1 signaling pathway. Cell Metab (2011) 2.22
Exploring techniques for vision based human activity recognition: methods, systems, and evaluation. Sensors (Basel) (2013) 2.22